AlphaTON Capital Receives Nasdaq Congratulations for Groundbreaking Cancer Research Tokenization Initiative

New York, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) --

AlphaTON Capital (NASDAQ: ATON), a specialized digital asset treasury company focused on developing the TON and Telegram ecosystem, and new pioneer in blockchain-based healthcare financing, today announced that Nasdaq has publicly congratulated the company on its innovative approach to funding cancer research through asset tokenization. The recognition was displayed prominently on the iconic Nasdaq Tower in Times Square, marking a significant milestone in the convergence of digital assets and medical research funding.

Transforming Cancer Treatment Through Tokenization

AlphaTON Capital's partnership with Cyncado Therapeutics represents a revolutionary approach to financing life-saving cancer research. By leveraging blockchain technology and asset tokenization, the company has created a transparent, accessible investment mechanism that connects global investors directly with promising oncology research programs.

"This recognition from Nasdaq validates our vision of democratizing access to healthcare innovation investments," said Brittany Kaiser, Chief Executive Officer of AlphaTON Capital. "Traditional pharmaceutical research funding has been limited to institutional investors and venture capital firms. Through tokenization, we're opening these opportunities to a broader supporter base while accelerating the path from laboratory discoveries to patient treatments."

A New Model for Medical Research Funding

The AlphaTON-Cyncado collaboration addresses critical challenges in cancer research funding:

• Enhanced Liquidity: Tokenized assets provide greater flexibility and market access
• Transparent Allocation: Blockchain technology ensures clear tracking of fund deployment
• Reduced Barriers: Lower minimum financial participation enables broader audience participation in medical innovation
• Accelerated Timelines: Streamlined capital access speeds up research and development cycles

Impact on Cancer Treatment Development

Cyncado Therapeutics, the beneficiary of this innovative funding approach, is developing next-generation cancer treatments targeting previously undruggable tumor pathways. The partnership has already enabled the advancement of multiple research programs that were previously constrained by traditional funding limitations.

"AlphaTON's exploration of co-developing this tokenization initiative with us has fundamentally changed how we approach research capitalization," stated Peter Malloy, CEO of Cyncado Therapeutics. "This funding model allows us to focus on science rather than spending years in funding roadshows."